olanzapine + lithium + valproate + carbamazepine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Manic or Mixed Episode Associated With Bipolar I Disorder
Conditions
Manic or Mixed Episode Associated With Bipolar I Disorder
Trial Timeline
Nov 1, 2005 → May 1, 2009
NCT ID
NCT00266630About olanzapine + lithium + valproate + carbamazepine
olanzapine + lithium + valproate + carbamazepine is a phase 3 stage product being developed by Eli Lilly for Manic or Mixed Episode Associated With Bipolar I Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00266630. Target conditions include Manic or Mixed Episode Associated With Bipolar I Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00266630 | Phase 3 | Completed |